Abstract: The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfonate transporter located in the cytoplasm membrane of the cell wherein said sulfonate transporter is capable of transporting said sulfonic acid construct across the cytoplasm membrane into the cytoplasm; (ii) a ?-glutamyl transferase (GGT; EC 2.3.2.2) which is modified to be located in the cytoplasm of the cell, wherein said ?-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct so as to release the cargo. Moreover, the present invention relates to the use of a cellular transport system for bringing a sulfonic acid construct which contains a cargo into a cell and releasing the cargo in the cell's cytoplasm. Further, the present invention relates to a ?-glutamyl transferase for hydrolyzing a sulfonic acid construct which contains a cargo.

Abstract: Provided is a compound having the structure: (SIG)-(SI-MOD)m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Abstract: The present invention relates to methods of cryopreservation and compositions for use in such methods where the methods utilise non-Newtonian fluid properties of the cryopreservation medium to modulate the viscosity of that medium to deliver an improved cryopreservation process.

Abstract: The present disclosure relates to a liquid surfactant composition containing a surfactant mixture, water and at least one amylase as defined herein. The present disclosure also relates to a method for cleaning textiles including providing a washing liquor by dosing a liquid surfactant composition, mixing this dosage into at least one solvent, and bring the resulting mixture into contact with the textiles.

Abstract: A coating for conversion of formaldehyde to carbon dioxide includes an alcohol/aldehyde oxidase and a formate oxidase immobilized on a solid particulate support; and a latex binder.

Abstract: A voltage indicator includes a polypeptide sequence comprising a voltage-sensitive opsin domain and a capture protein domain arranged and disposed to capture a fluorescent dye ligand. When the fluorescent dye ligand is captured and the voltage indicator is bound to a cell membrane, an increase in voltage across the cell membrane causes an increase in fluorescent emission.

Abstract: Lactic acid is obtained by a method including (A) a step of continuous fermentation wherein a fermentation culture medium of a microorganism having an ability of lactic acid fermentation is filtered through a porous membrane having an average pore size of not less than 0.01 ?m and less than 1 ?m with a transmembrane pressure difference within the range of 0.1 to 20 kPa, and the permeate is collected, while retaining the non-permeated liquid in or returning the non-permeated liquid to the culture, and adding a fermentation feedstock to the culture; (B) a step of filtering the permeate obtained in Step (A) through a nanofiltration membrane; and (C) a step of distilling the permeate obtained in Step (B) under a pressure of not less than 1 Pa and not more than atmospheric pressure, at 25° C. to 200° C. to recover lactic acid.

Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.

Abstract: The present invention relates to a solution for the preservation of cells from placental blood, from bone marrow and from peripheral blood.

Abstract: It is an object of the present invention to provide a fluorescence imaging probe capable of selectively visualizing target cells such as cells expressing ?-galactosidase (lacZ expressing cells) at a single-cell level in a red fluorescence region, and of performing co-staining together with GFP.

Abstract: The invention refers to a method and a device for the phenotypic detection of carbapenemases and carbapenemase producers by adding a substrate of general formula A-(L)-M1-(X)—Z, where M1 is a carbapenem backbone, A or Z is a quencher, the other one of the two, Z or A, is a fluorophore, L is an optional linker, X is an optional leaving group for linking Z to the carbapenem backbone, and Z is an optional leaving group, to a sample suspected of containing such carbapenemase producers and/or carbapenenmases. The invention further refers to a method for the phenotypic detection of resistant bacteria, in particular 3MRGN or 4MRGN, by releasing the enzymes of a bacterial culture into a lysate during lysis and then subjecting the lysate, as the sample to be analyzed, to an aforementioned method in order to phenotypically detect the presence of resistance-conferring carbapenemases.

Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.

Abstract: According to one broad aspect of this disclosure, a method is provided for producing polyhydroxyalkanoates (PHA) from organic waste. The method comprises homogenizing organic waste to obtain a feedstock that has 1:1 to 3:1 (w/w) water to organic waste ratio. The feedstock is inoculated with an inoculum of acidogenic fermentative bacteria in order to obtain an inoculated feedstock. The inoculated feedstock is incubated for 5 to 10 days, 3 to 10 days, optionally 7 days, optionally 3 days, to obtain a fermentation broth. The fermentation broth comprises volatile fatty acids (VFAs) and undigested organic waste. The fermentation broth is filtered with a filter with a pore size ranging from 0.2 ?m to 500,000 NMWC to remove the acidogenic fermentative bacteria and undigested organic waste, to obtain a clarified broth comprising concentrated VFAs. The clarified broth and high-PHA producing bacteria are incubated to produce intracellular PHA granules in the high-PHA producing bacteria.

Abstract: The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

Abstract: The present invention relates to an enzymatic electrode comprising a conductive surface and wherein a conjugate comprising at least one enzyme molecule is covalently bound to the conductive surface. The electrode is suitable for continuous analyte monitoring, particularly for continuous glucose monitoring (CGM) with glucose oxidase (GOD) as enzyme molecule. Further, the invention relates to an electrochemical sensor for measuring the concentration of an analyte, e.g. glucose under in vivo conditions comprising the enzymatic electrode.

Abstract: Provided is a diagnostic kit for determining infection with Methicillin-Resistant Staphylococcus aureus (MRSA) in a specimen, and a method for determining the infection with MRSA using the diagnostic kit is performed by visually observing a color change after LAMP reaction, and the color change is caused by a change in a magnesium concentration and confirmed using a specific dye compound which sensitively reacts with magnesium ions. The amplification of the MRSA DNA is performed using the loop-mediated isothermal amplification (LAMP), so that the diagnostic kit has advantages of being conveniently used anytime and anywhere and quickly diagnosing.

Abstract: Disclosed in the present invention are an immobilized cycloaliphatic peptide acyltransferase and a preparation method and use thereof. The cycloaliphatic peptide acyltransferase is immobilized on a carrier; the cycloaliphatic peptide acyltransferase is derived from natural or artificial mutants or variants thereof, or can be obtained by introducing a foreign cyclic acyltransferase gene and transforming thereafter; the material of the carrier is selected from an inorganic carrier or a polypropylene resin carrier. Also disclosed in the present invention are the preparation method for the immobilized cycloaliphatic peptide acyltransferase and uses thereof.

Abstract: A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.

Abstract: The invention relates to platinum and rhenium complexes of formula (I) that may be used as imaging agents. In particular, the invention relates to imaging agents, for example imaging agents for use in the imaging of peroxisomes. Certain embodiments of the invention relate to compounds per se. Other embodiments relate to a process for the preparation of compounds and to the use of compounds as imaging agents.